IFF unwinds its DuPont mistake, one business at a time

SOMETIMES A merger of equals turns out to be a lesson in arithmetic. International Flavors & Fragrances, which combined with DuPont's Nutrition & Biosciences unit in a $26bn all-stock deal in early 2021, is now dismantling the combined entity piece by piece. On May 29th it agreed to sell most of its Food Ingredients business to CVC Capital Partners for $4.3bn. That is the latest in a string of 13 divestitures, collectively fetching nearly $10bn, as IFF shrinks back to the scale and margin profile it once had before the marriage went wrong.

The surface framing is portfolio optimisation. The deeper story is post-merger repair. IFF paid a premium in DuPont stock to acquire a sprawling platform that included food ingredients, pharma solutions, animal nutrition, and biosciences. It has since concluded that much of the platform was not a fit for its core expertise in flavours and fragrances, that the acquired businesses carried lower margins than its original ones, and that the combined balance sheet was too leveraged for the economic climate. The Food Ingredients sale is the capstone of that painful rethinking.

The numbers tell a straightforward story about why the business was shed. In 2025, Food Ingredients generated $3.1bn in sales but only $430m of EBITDA, an earnings-before-interest,taxes,depreciation-and-amortisation margin of 13.9%. By comparison, IFF's remaining businesses are markedly more profitable: Health & Biosciences posted a 26% EBITDA margin on $2.28bn of sales, Scent achieved 20.8% on $2.48bn, and Taste earned 19.3% on a similar revenue base. Food Ingredients was the largest segment by revenue but the weakest by profitability. The incentive to strip it out, hence, is not ideological but arithmetic.

The arithmetic is also what explains the $1.15bn goodwill write-down IFF recorded in 2025. Goodwill is the excess of purchase price over the fair value of identifiable assets; when a business is expected to fetch less on sale than was originally paid, the difference is written off. The charge reflected IFF's candid acknowledgment that Food Ingredients, as a standalone asset, was worth less than the allocation embedded in the DuPont deal. The $4.3bn enterprise value - approximately 10 times EBITDA - is not a distress price, but it is a sober one. CVC sees value in scale, clean-label demand, and proprietary texturant technology. IFF sees value in the cash it recovers and the balance sheet it repairs.

To be sure, the divestiture is not a clean exit. IFF is retaining a 9.9% minority stake, worth approximately $200m, along with a board seat and an agreement for continued commercial cooperation. That structure is worth a moment's scrutiny. It allows IFF to keep participating in the upside without bearing the operational burden of a low-margin business. It also signals that IFF expects the divested unit to remain a supplier of overlapping ingredient categories. The arrangement is tidy so long as the two companies do not compete head-to-head for the same food and beverage accounts. If they do, the minority stake will become an awkward distraction.

The broader trajectory is more revealing than any single transaction. Since the DuPont merger, IFF has sold its pharma solutions business to Roquette for $2.85bn, offloaded its soy crush and lecithin operations to Bunge, and shed smaller units including Savory Solutions, Flavor Specialty Ingredients, and a fruit preparation business to Frulact. Each sale was justified as a return to core. Taken together, they form a pattern of strategic retreat. The combined company was too broad, too leveraged, and too far from the high-margin flavour and fragrance work that originally distinguished it. The retreat is not humiliation; it is discipline. IFF repaid $2.9bn of debt in 2025, bringing net leverage from over 4 times down to 2.6 times. Proceeds from the Food Ingredients sale - roughly $3.8bn in cash - are earmarked for further deleveraging, share repurchases, and reinvestment.

The post-merger IFF that emerges from this process is smaller but more coherent. With Food Ingredients gone, the company's three remaining businesses - Taste, Scent and Health & Biosciences - together command roughly 19% to 26% EBITDA margins and serve markets where innovation, not volume, is the source of pricing power. Health & Biosciences, in particular, is well positioned for the long-term demand for probiotics, enzymes and bioactive ingredients. The segment's 26% margin and 7% EBITDA growth in 2025 make it the growth engine around which the rest of the restructured company will likely orbit.

The risk is that the smaller IFF loses too much scale too quickly. Food Ingredients was 30% of revenue. Its absence creates a 5% drag on reported sales even before the final close, expected by the second quarter of 2027. IFF's revenue declined in 2025 to $10.9bn from the prior year, and the company expects further contraction in 2026 as older businesses close out. The company has guided to organic growth of 1-4% in 2026, which is modest but credible given the strength of the remaining segments. The question for investors is whether the margin improvement from a leaner portfolio compensates for the lost top line. On the evidence so far, it does: the retained businesses collectively earn a higher return on capital and generate cash flow at a faster rate than the conglomerate average.

AInvest's aggregate signal labels IFF a Buy, reflecting the market's willingness to reward the simplification. The stock's market capitalisation of roughly $20bn implies a valuation that prices in some recovery but not perfection. The trailing price-to-earnings ratio of around 24.5 times is not cheap for a mid-growth chemicals company. It is justified, however, only if the post-divestiture IFF sustains high-single-digit EBITDA growth and converts more of that earnings power into free cash flow. The structural thesis is that a focused portfolio of high-margin, innovation-led businesses is worth more per dollar of earnings than the broad, debt-laden conglomerate it replaced. That is plausible, but it is not automatic.

The lesson for corporate America is less about IFF and more about the habit of merger-fuelled hubris. The DuPont-NB deal was struck in 2019, a year of bullishness, cheap debt, and an unshakeable conviction that scale trumped focus. It is the familiar pattern of post-merger disillusionment: the integration is harder than promised, the synergies are elusive, the balance sheet is heavy, and the exit is conducted with a smile. IFF's management has been honest about the misstep and decisive in reversing it. That deserves credit, even if the original decision deserved second thoughts much earlier than they apparently arrived. Better late than never is still better than never. But it would be wiser to have started sooner.

For investors, the relevant test is simple. Does the restructured IFF earn its premium by delivering margin growth, cash flow and innovation from a leaner platform, or does it merely replicate the low-conviction economics of the businesses it kept? The evidence points to the former. The margin gap between the divested and retained businesses is too wide to be accidental. The capital return programme is too large to be cosmetic. Whether the stock's current valuation fully captures that transition is a separate question. The structural work, at least, is done.